Pacira BioSciences, Inc.·4

Feb 3, 6:24 PM ET

WILLIAMS KRISTEN 4

Research Summary

AI-generated summary

Updated

Pacira (PCRX) CAO Kristen Williams Sells 30,271 Shares

What Happened

  • Kristen Williams, Chief Administrative Officer of Pacira BioSciences (PCRX), disposed of a total of 30,271 shares in two related transactions totaling approximately $621,635.
    • On 2026-01-30, 17,134 shares were withheld by the issuer to cover tax withholding on vested restricted stock units (17,134 shares × $20.54 = $351,932).
    • On 2026-02-02, 13,137 shares were sold in an open-market transaction at $20.53 per share for proceeds of $269,703. This sale was executed under a pre-existing Rule 10b5-1 trading plan.
  • These were sales/withholdings (not purchases). Withholding for taxes on RSUs is a routine administrative event; the open-market sale was pre-planned under a 10b5-1 plan.

Key Details

  • Transaction dates and prices:
    • 2026-01-30 — 17,134 shares withheld for taxes at $20.54 (F1) — $351,932.
    • 2026-02-02 — 13,137 shares sold at $20.53 (F2) — $269,703; sale executed pursuant to a Rule 10b5-1 plan.
  • Combined proceeds: ~$621,635.
  • Shares owned after the transactions: not specified in the summary provided (check the full Form 4 for post-transaction holdings).
  • Footnotes:
    • F1: Shares withheld by the issuer to cover tax withholding on vesting of restricted stock units.
    • F2: The open-market sale was effected pursuant to a pre-established Rule 10b5-1 trading plan.
  • Filing timeliness: Form filed 2026-02-03 for transactions on 2026-01-30 and 2026-02-02; no late filing flag was indicated.

Context

  • The 17,134-share event was a tax-withholding on RSU vesting (an administrative disposition), not a discretionary sale for cash.
  • The 13,137-share sale was under a Rule 10b5-1 plan, meaning the trade was pre-scheduled and not necessarily a reflection of near-term sentiment.
  • Sales and withholding reported on Form 4 are routine insider disclosures; they are factual records of transactions and do not by themselves prove management’s view of the company’s prospects.